ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2000

Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA

Janis Timsans1, Raine Tiihonen2, Jenni Kauppi3, Vappu Rantalaiho4, Anne Kerola1, Kia Hakkarainen5, Tiina Lehto6, Hannu Kautiainen7 and Markku Kauppi1, 1Päijät-Häme Central Hospital, Department of Rheumatology, Lahti, Finland, 2Päijät-Häme Central Hospital, Department of Orthopedics and Traumatology, Lahti, Finland, 3Päijät-Häme Central Hospital, Unit of Physiatry and rehabilitation medicine, Lahti, Finland, 4Tampere University, Faculty of Medicine and Health Technology; Tampere University Hospital, Centre for Rheumatic Diseases, Tampere, Finland, 5Päijät-Häme Central Hospital, Department of Nephrology, Lahti, Finland, 6Fimlab Laboratoriot Oy, Department of Clinical Chemistry, Lahti, Finland, 7Folkhälsan Research Center, Helsinki, Finland

Meeting: ACR Convergence 2025

Keywords: Arthroplasty, hyperuricemia, Osteoarthritis, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Serum uric acid (SUA) has been linked to various health conditions, including osteoarthritis (OA), though findings have been inconsistent. Data on the relationship between SUA and OA in large joints are particularly limited, and its potential association with the need for large joint replacements (LJRs) has not been previously investigated. This study aimed to examine the association between SUA levels and the incidence of LJRs.

Methods: Data were drawn from the GOAL (GOod Ageing in Lahti region) study, a prospective cohort study of individuals aged 52–76 years in Finland’s Lahti region. Baseline data included SUA levels, other laboratory parameters, comorbidities, medication use, lifestyle factors, and socioeconomic variables. Information on LJRs was obtained from the National Care Register for Social Welfare and Health Care. After excluding participants with prior LJRs or cancer diagnoses, 2,403 individuals (1,115 women and 1,288 men) were included. The incidence of large joint arthroplasty over a 12.7-year follow-up was analyzed in relation to SUA levels, adjusting for age, sex, body mass index (BMI), and Charlson Comorbidity Index (CCI). Hyperuricemia was classified as renal when SUA was ≥420 μmol/L (≈7 mg/dL) and estimated glomerular filtration rate (eGFR) ≤67 ml/min/1.73 m² (25th percentile), and as metabolic when SUA was ≥420 μmol/L with eGFR >67 ml/min/1.73 m².

Results: Over the 12.7-year follow-up period, a total of 303 LJRs were performed in the study population, including 133 hip replacements, 161 knee replacements, 8 shoulder replacements, and 1 elbow replacement; no ankle replacements were reported. In models adjusted for age, sex, BMI, and CCI, higher SUA levels were associated with a lower incidence of LJRs (Figure 1). When analyzing the incidence rate ratio across SUA categories (< 300 µmol/L, 300–359 µmol/L, 360–419 µmol/L, ≥420 µmol/L), a statistically significant decreasing trend in LJRs with increasing SUA was observed (p = 0.006; Table 1). While the adjusted cumulative incidence of first LJR increased with higher SUA, there was no substantial difference between individuals with metabolic versus renal hyperuricemia (Figure 2).

Conclusion: In our study population, individuals with higher SUA levels were less likely to undergo LJR during the 12.7-year follow-up period. This finding has not been previously demonstrated. Future studies are needed to determine whether uric acid has a protective effect on cartilage in large joints, potentially reducing cartilage degradation. Replicating our findings in other studies and further investigating the impact of uric acid on cartilage health are essential.

Supporting image 1Figure 1. Panel A: Association of serum uric acid (SUA) level and incidence of arthroplasties. Panel B: Log incidence rate ratio of arthroplasties by SUA level. Denominator of IRR is SUA 420 µmol/L.

The results are adjusted for age, sex, body mass index and Charlson Comorbidity Index.

Supporting image 2Table 1. Incidence and incidence rate ratio (IRR) for incident large joint replacements across different SUA groups.

SUA, serum uric acid; LJRs, large joint replacements; pyrs, person-years; IRR, incidence rate ratio

Supporting image 3Figure 3. Adjusted cumulative incidence of first LJR.

SUA, serum uric acid; LJR, large joint replacement


Disclosures: J. Timsans: None; R. Tiihonen: None; J. Kauppi: None; V. Rantalaiho: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 1, Johnson&Johnson, 6, Medac, 6, Novartis, 6, Viatris, 6; A. Kerola: None; K. Hakkarainen: None; T. Lehto: None; H. Kautiainen: None; M. Kauppi: None.

To cite this abstract in AMA style:

Timsans J, Tiihonen R, Kauppi J, Rantalaiho V, Kerola A, Hakkarainen K, Lehto T, Kautiainen H, Kauppi M. Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/can-uric-acid-protect-joints-lower-incidence-of-large-joint-replacements-among-individuals-with-higher-sua/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-uric-acid-protect-joints-lower-incidence-of-large-joint-replacements-among-individuals-with-higher-sua/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology